WVE
Research Snapshot
Static fundamentals, valuation context, and investor signals for WAVE LIFE SCIENCES LTD. (WVE).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-39.4%
ROIC, -440.5% FCF margin
Growth
16.3%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 6.5x current ratio
Superinvestors
1
Top: Lee Ainslie (0.9%)
Strengths to research
- Revenue compounded at 16.3% over five years.
- Debt/equity looks manageable at 0.0x.
- 10 annual periods are available for trend analysis.
Watchouts
- Free cash flow margin is negative at -440.5%.
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for WVE.
Grade F
16
/ 100
Financial Charts
No financial data available for WVE (annual).
1 superinvestors own WVE
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Lee Ainslie Maverick Capital | 10,161,399 | $74M | 0.86% | 0.0% |